早期多模式非药物干预在老年人认知保存方面的有效性
Sun-Wung Hsieh1,2,3,4, Shih-Fen Hsiao5,6, Lih-Jiun Liaw5,6
1Department of Neurology, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
概括
多模式非药物干预 (MNPI) 在老年人中显著改善了认知保存. 早期干预显示出更大的益处,特别是在远程记忆,定向,绘画和语言技能方面.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 认知健康 认知健康
背景情况:
- 多模式非药物干预 (MNPI) 已被认为可以延缓老年人的认知衰退.
- 启动MNPI以最大限度地提高认知保存的最佳时间仍然不太被探索.
研究的目的:
- 为了比较MNPI在保持老年痴呆症和没有痴呆症的老年人认知功能的有效性.
- 评估MNPI对认知领域以及痴呆症行为和心理症状 (BPSD) 的影响.
主要方法:
- 43名老年参与者 (18名非痴呆症,25名痴呆症) 接受了16周的每周两次MNPI (身体健康,中国毛细血管,绘画).
- 认知功能 (MMSE,CASI,CDR) 和BPSD (NPI) 在干预前和后被评估 (1年随访).
主要成果:
- 与痴呆症组相比,非痴呆症组在远程记忆 (100% vs 68%),定向 (94.4% vs 48%),绘画 (94.4% vs 64%) 和语言 (77.8% vs 48%) 的认知维护显著更高.
- 在非痴呆症组中,保存的认知包括远程记忆 (100%),定向 (94.4%) 和绘画 (94.4%).
- 在痴呆症组中,保存的认知包括注意力 (72%),远程记忆 (68%),近期记忆 (64%) 和绘画 (64%).
- 在BPSD的整体改善为55.6%.
结论:
- 早期启动MNPI为老年人的认知保存提供了显著的好处.
- 特别地,MNPI增强了远程记忆,定向,绘画和语言技能.
- MNPI还有助于改善痴呆症的行为和心理症状.
更多相关视频
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
01:30Cognitive Development During Adulthood
93
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
93
01:22Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180